Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2021 | Biomarkers for novel RCC and urothelial carcinoma treatments

Andrew Schmidt, MD, B.Pharm, Dana-Farber Cancer Institute, Boston, MA, discusses the significance of biomarkers for novel renal cell carcinoma (RCC) and urothelial carcinoma treatments. The development of new immunotherapy regimens, such as immune checkpoint inhibitors and antibody drug conjugates, may improve survival outcomes for some patients. However, a lack of known biomarkers means populations who could derive benefit from these therapies cannot be identified. This interview took place during the 2021 Genitourinary Cancers Symposium.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.